EXECUTIVE COMMITTEE

 
 
Julia P. Gregory
Julia P. Gregory
Chief Executive Officer

Julia P. Gregory

Chief Executive Officer


Julia P. GregoryMs. Gregory has been Chief Executive Officer since November 2013. Prior to that time, she was Executive Vice President and Chief Financial Officer, since July, 2012. Prior to ContraFect, Ms. Gregory was President and CEO of Five Prime Therapeutics, Inc., a clinical-stage, privately held biotechnology company discovering and developing innovative protein and antibody therapeutics in the fields of oncology and immunology. Prior to Five Prime, Ms. Gregory was Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Ms. Gregory has been actively involved in a variety of public and private financings, including a private equity agreement designed to provide financing of up to $550 million for Lexicon and Lexicon's $220 million initial public offering. While at FivePrime and Lexicon, she led transactions for several strategic partnerships including those with GlaxoSmithKline, Human Genome Sciences, Genentech, Inc., Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. In addition, she led the negotiations for Lexicon's acquisition of the chemistry company that provided the foundation for Lexicon's novel drug programs. Prior to joining Lexicon, Ms. Gregory was an investment banker where she served as the head of investment banking for Punk, Ziegel & Company, a specialty technology and healthcare investment banking firm and was an investment banker with Dillon, Read & Co., Inc. She currently serves as a Director on the board of Clinipace on behalf of and as Special Advisor to Morgan Stanley Expansion Capital and on the board of The Global TB Alliance for Drug Development, primarily funded by the Gates Foundation.

Ms. Gregory received her B.A. from George Washington University's Elliott School of International Affairs where she was elected to Phi Beta Kappa and her M.B.A. from the Wharton School of the University of Pennsylvania.

David B. Huang, M.D., Ph.D.
Dr. David B. Huang
Chief Medical Officer

David B. Huang, M.D., Ph.D., J.D.

Chief Medical Officer

David B. Huang, M.D., Ph.D.Dr. Huang has more than 10 years of clinical research and industry experience. Prior to joining ContraFect, Dr. Huang served as the Global Medical Director of Medical Affairs for Pfizer Inc., where he played a key role in the development efforts of Zyvox for Gram-positive infections. Previously, he was the Associate Director of Clinical Development for BoehringerIngelheim GmbH, where he played a key role in the development of Aptivus and Viramune XR for HIV infections and compounds for HCV infections. Dr. Huang previously served as an Assistant Professor at Baylor College of Medicine where his research interest was focused on Gram-negative pathogens, and currently serves as an Adjunct Clinical Professor at the Rutgers New Jersey Medical School, and is an attending physician at the Veterans Affairs Medical Center at Manhattan.

Dr. Huang received his M.D. and Ph.D. from the University of Texas at Houston Medical School. He is board certified in internal medicine and infectious diseases and is a fellow of the American College of Physicians and Infectious Diseases Society of America. He completed his internal medicine residency at the University of Texas at Southwestern and his infectious diseases fellowship at Baylor College of Medicine. Dr. Huang received his J.D. from Pace Law School and is a member of the New York Bar Association. Dr. Huang's research interest has focused on the epidemiology, pathogenesis and treatment of viruses and bacteria, including multi-drug resistant pathogens, and has resulted in over 100 peer-reviewed publications.

Michael Wittekind, Ph.D.
Dr. Michael Wittekind
Chief Scientific Officer

Michael Wittekind, Ph.D.

Chief Scientific Officer

Michael Wittekind, Ph.D.Dr. Wittekind has more than 20 years of industry experience in biotechnology research and management. Prior to joining ContraFect, Dr. Wittekind served as the Executive Director of Research for Amgen Inc, where he directed the Protein Science Department at the Amgen-Seattle site. While at Amgen, he was involved in the discovery efforts for multiple protein therapeutics currently undergoing clinical trials, including antibodies, antibody-drug conjugates, and protein fusions. Previously, Dr. Wittekind was the Director of Process Development for Phylos Inc, where he played a key role in the development of alternate scaffold therapeutic discovery, design, and production. Dr. Wittekind has also served as the Associate Director of the Gene Expression & Protein Biochemistry Department of the Bristol-Myers Squibb Pharmaceutical Research Institute, directing groups in both the Lawrenceville and Hopewell NJ sites leading structural biology research as well as protein and small molecule therapeutic efforts.

Dr. Wittekind received his Ph.D. from the University of Wisconsin-Madison in Biochemistry and followed with postdoctoral studies at the University of Washington. Dr. Wittekind's research interests have encompassed genetics, molecular biology, structural biology, and engineering of novel antibodies and proteins, resulting in over 40 publications and patents.

Barry Kappel, Ph.D., MBA
Dr. Barry Kappel
SVP, Business Development

Barry Kappel, Ph.D., MBA

Senior Vice President, Business Development

Barry Kappel, Ph.D., MBADr. Kappel joined ContraFect in 2009 as the company's second employee and the Head of Business Development. Since the beginning, Dr. Kappel has been involved in all aspects of the company, including licensing of the company's key technologies, participation in the financings of the company, and establishing scientific collaborations with academic and corporate partners.

Dr. Kappel previously was a Senior Consultant at Easton Associates, LLC, a life science consulting firm. In this capacity, he performed a wide range of activities, including the assessment of preclinical and clinical compounds for Pharmaceutical and Biotechnology companies.

Dr. Kappel received his B.A. in chemistry from Emory University. He subsequently obtained his Ph.D. in immunology and pharmacology from the Weill Graduate School of Medical Sciences and the Memorial Sloan-Kettering Cancer Center. Dr. Kappel holds an MBA from the S.C. Johnson Graduate School of Management at Cornell University.

Daniel Couto
Daniel Couto
SVP, Manuf. & Ops.

Daniel Couto

Senior Vice President, Manufacturing & Facility Operations

Daniel CoutoMr. Couto has more than 20 years of experience in operations management. Prior to joining ContraFect, he served as a Vice President of Commercial Manufacturing Operations for Merck Sharp & Dohme Biologics UK Ltd. Previously, he was Director of Manufacturing for Nuvelo Inc., where he was responsible for 7 World Wide Contract Manufacturing sites. Mr. Couto also served in Director positions at Genzyme Transgenics Corp., Advanced Biosystems Corp., ImmuCell Corp., and Sepracor Corp. Mr. Couto holds patents for several novel separation technologies such as Bulk Protein Crystallization, HPTFF, and SMB.

Mr. Couto received his B.S. degree in chemical engineering from Rensselaer Polytechnic Institute.

Nancy Dong
Nancy Dong
VP, Controller

Nancy Dong

Vice President, Controller

Nancy DongMs. Dong has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing and Alley Corp prior to her role as Vice President of Finance and Administration at DCM, a tele-services firm supporting the performing arts. Ms. Dong also held the positions of COO/CFO at Semaphore, a project management software development firm.

Ms. Dong received her B.A. degree from Yale University and a MPPM degree from The Wharton School at the University of Pennsylvania. She started her career as a management consultant at Ernst & Young.

Michael Messinger, CPA
Michael Messinger
VP, Finance

Michael Messinger, CPA

Vice President, Finance

Michael Messinger, CPAMr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmaceuticals, Inc. In this capacity, he was responsible for the financial management of Lexicon's partnership with Symphony Capital, LLC, in addition to coordinating fiscal and program management concerning Lexicon's development programs.

Mr. Messinger received his B.B.A degree in accounting from the University of Michigan. He started his career as an auditor at Ernst & Young, LLP.

 
Natalie Bogdanos, Esq.
Natalie Bogdanos
General Counsel

Natalie Bogdanos, Esq.

General Counsel

Natalie Bogdanos, Esq.Ms. Bogdanos has more than 15 years of in-depth legal experience across many areas of law including contract, intellectual property, licensing, regulatory, corporate governance, securities and litigation.

Prior to joining ContraFect, Ms.Bogdanos served as Associate General Counsel at Memorial Sloan-Kettering Cancer Center (MSKCC). At MSKCC, she held a joint appointment with the Office of the General Counsel and the Office of Technology Development (OTD), providing legal counsel and guidance to various departments throughout the institution while having sole responsibility for the legal oversight of the OTD.

Previously, Ms. Bogdanos served as General Counsel at Enzo Biochem, Inc. (Enzo), a publicly traded international biotechnology & life sciences company focused on developing research tools, diagnostics & therapeutics, and providing test services to the medical community. During her tenure at Enzo, she provided legal guidance and business advice regarding all aspects of research, development, manufacture, use, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies.

After graduating law school, Ms. Bogdanos worked as an associate at Amster, Rothstein & Ebenstein. Ms. Bogdanos has also served as a legal consultant to pharmaceutical companies and is presently a faculty member at the Practising Law Institute. Prior to attending law school, she was a research technician at the Public Health Research Institute where her work focused on Staphylococcus aureus.

Ms. Bogdanos is an attorney licensed to practice before the United States Patent and Trademark Office. She is admitted to practice law in New York, the United States District Court, Southern & Eastern District of New York and the United States Court of Appeals for the Federal Circuit. Ms. Bogdanos received her Juris Doctor from New York Law School and her Bachelor of Arts in Biology, with honors, from Queens College of the City University of New York.

 

DIRECTORS

 
 
Sol Barer, Ph.D.
Dr. Sol Barer
Chairman

Sol Barer, Ph.D.

Chairman

Sol Barer, Ph.D. Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served as Executive Chairman from June 16, 2010 until December 31, 2010. Previously he was appointed President in 1993 and Chief Operating Officer in 1994.

Dr. Barer holds numerous professional awards, including the "Key Visionary Award" (Pontifical Council of Culture, Vatican and the Stem for Life Foundation), "Chairman's Award" (R&D Council of New Jersey), "Corporate Leadership Award" (Multiple Myeloma Research Foundation "Lifetime Achievement Award" (International Myeloma Foundation), "Outstanding Individual" (Biotech Meeting 2010), "Dream & Promise Award" (Children's Brain Tumor Foundation), "Odyssey Award" (Center for Medicine in the Public Interest), "Corporate Vision Award" (Gilda's Club), "Sparkle of Hope Award" (Community Hope), "Master Entrepreneur (Ernst & Young), "Hall of Distinguished Alumni" (Rutgers University Alumni Federation), "Dr. Sol J. Barer Award for Vision, Innovation and Leadership" (BioNJ), "Science and Technology Industry Medal" (R&D Council of NJ), "Rutgers University Graduate School Distinguished Alumnus Award," "Winthrop-Sears Medal" (Chemists Club and the Chemical Heritage Foundation), "Albert Einstein Award in Life Sciences" (Global Capital Associates and Jerusalem Fund, Israel), and "DART/NYU Biotechnology Achievement Award" (Biotechnology Study Center of the NYU School of Medicine).

Dr. Barer was named one of "25 Leadership Legends of NJ" (NJBiz), "The 50 Most Powerful People in N.J. Health Care," inducted into the NJBiz Hall of Fame and named as one of NJ's top 10 scientists by New Jersey Business.

Dr. Barer serves as Chairman of the Board of the public companies InspireMD, Medgenics and Stratus Media Group (RestorGenex) and private companies Centrexion, Cerecor, ContraFect and Edge Therapeutics, and is on the Board of Directors of Aegerion Pharmaceuticals and Amicus Therapeutics. He is an advisor to biotechnology/medical companies and not for profit organizations.

In 2011 Dr. Barer was Chairman of the University of Medicine and Dentistry of New Jersey Governor's Advisory Committee which recommended sweeping changes in the structure of New Jersey's medical schools and public research universities, was a Commissioner of the NJ Commission on Science and Technology, was a member of the Board of Trustees of Rutgers - The State University of New Jersey and served as Chair of the Board of Trustees of BioNJ the New Jersey biotechnology organization.

Dr. Barer received a Ph.D. in organic chemistry from Rutgers University and B.S. from Brooklyn College.

Dr. Roger Pomerantz
Dr. Roger Pomerantz
Vice Chairman

Roger J. Pomerantz, M.D., F.A.C.P.

Vice Chairman

Roger Pomerantz Dr. Pomerantz was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz currently serves as the Chairman of the Board of Directors for Seres Health Inc.

Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed eight drugs approved world-wide in important diseases, including HIV, HCV, and tuberculosis.

David A. Scheinberg, M.D., Ph.D.
Dr. David A. Scheinberg
 

David A. Scheinberg, M.D., Ph.D.

Chairman, Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute

David A. Scheinberg, M.D., Ph.D.

Dr. Scheinberg also founded and chairs the Experimental Therapeutics Center at Memorial Sloan-Kettering Cancer Center, co-chairs the Pharmacology Graduate Program at the Weill-Cornell University Medical College, and is a professor in the Gerstner-Sloan Kettering Graduate School at MSKCC as well as at Weill Cornell Medical College. From 1992 until 2003 he was Chief of Leukemia Service at Memorial Hospital. In 2013 he was Interim Director of Sloan-Kettering Institute.

A physician-scientist, Dr. Scheinberg specializes in the care of patients with leukemia. He investigates new therapeutic approaches to cancer, both in the hospital and in the laboratory. The focus of his research is the discovery and development of novel, specific immunotherapeutic agents. Eight therapeutic agents developed by Dr. Scheinberg-which include the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor-specific fusion oncogene product vaccines-have reached human clinical trials. He has published more than 200 peer-reviewed papers, chapters and books.

In the private sector, Dr. Scheinberg was Founder and Chairman of the Board of Active Biotherapeutics, Inc., which was acquired by Progenics Pharmaceuticals. He is currently a Director of Progenics Pharmaceuticals, a public company, and a member of the scientific advisory boards ofOncopep and Ensysce pharmaceuticals. Dr. Scheinberg founded and is a Director of the Therapeutics Discovery Institute, a non-profit drug discovery corporation serving Rockefeller University, Weil Cornell Medical College and Memorial Sloan Kettering Cancer Center.He advises charitable foundations, cancer centers, and biotech companies and sits on several journal editorial boards.

Dr. Scheinberg received his A.B., cum laude, distinction in all subjects, from the College of Arts and Sciences, Cornell University, in 1977. He earned his M.D. from Johns Hopkins University in 1983, and his Ph.D. from Johns Hopkins University School of Medicine, Department of Pharmacology and Experimental Therapeutics, in 1983.

Isaac Blech
Isaac Blech
 

Isaac Blech

Founder and private financier of biotechnology companies

Isaac Blech Mr. Blech is among the most successful company founders and private financiers in the biotechnology industry. As a pioneer in the field, he established eight biotechnology companies, all of which were subsequently brought public. These companies include Celgene, the third largest independent biotechnology company in the world, which is a member of the S&P 500 and currently has a market capitalization exceeding $65 billion. These companies have achieved an aggregate market capitalization exceeding $75 billion.

Mr. Blech earned a B.A. degree from Baruch College in 1975.

Cary W. Sucoff
Cary W. Sucoff
 

Cary W. Sucoff

Owner, Equity Source Partners LLC, an advisory and consulting firm

Cary W. Sucoff Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated in the financing of more than 100 public and private companies, raising approximately $500 million of equity capital and playing a role in securing financing for biotech companies including Amgen, Centecor, Genzyme, Genentech, Icos, PathoGenesis, Vaxgen and Biotime.

Since 2011, Mr. Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm.

In addition to ContraFect, Mr. Sucoff currently serves on the Board of Directors of Cerecor, Inc., Premier Alliance Group, Inc., The SpendSmart Payments Corp. (SSPC) and Advanced Research and Photonics. Mr. Sucoff is the President of New England Law/Boston, has been a member of the Board of Trustees for over 25 years and is the current Chairman of the Endowment Committee. Mr. Sucoff recently taught a third-year seminar, "Perspectives In Law: Lawyers as Entrepreneurs and as Representatives of Entrepreneurs."

Mr. Sucoff received a B.A. from SUNY Binghamton in 1974 and a J.D. from New England School of Law in 1977, where he was managing editor of the Law Review and graduated magna cum laude. He has been a member of the Bar of the State of New York since 1978.

Shengda Zan
Shengda Zan
 

Shengda Zan

President, Zongyi Group

Shengda Zan

Mr. Zan, a Chinese entrepreneur and investor, founded the ZONGYI Group in 1987. The ZONGYI Group is a diversified business group of global operations, focusing on clean energy, information technology, strategic investments and asset management. Jiangsu Zongyi Share Co. Ltd, the core company of the ZONYI Group which formally listed on Shanghai Stock Exchange in 1996, is the composition of some of most important Chinese Stock Indexes, including the HS300 INDEX. In recent years, the ZONGYI Group has been committed to investments in the United States, including a solar plant built and operated in New Jersey with a capacity of 20MW, which is one of the largest solar plants in the Eastern United States.

Mr. Zan enjoys a reputation in the area of investment, and a large amount of his investment projects are strategic investments in China. One of these investments is the Jiangsu Yanghe Share Co.Ltd, the company with the highest market value in the Shenzhen Stock Exchange. Several of the investment projects of Mr. Zan in the past two years include Huishan Holding (Group) - the largest dairy enterprise in China, Zking Property & Casualty Insurance, Chang'an Property & Liability Insurance, and Aeon Life Insurance. In the fourth quarter of 2012, Mr. Zan became the second largest shareholder of China International Futures, the biggest future company in China.

Julia P. Gregory
Julia P. Gregory
 

Julia P. Gregory


Julia P. GregoryMs. Gregory has been Chief Executive Officer since November 2013. Prior to that time, she was Executive Vice President and Chief Financial Officer, since July, 2012. Prior to ContraFect, Ms. Gregory was President and CEO of Five Prime Therapeutics, Inc., a clinical-stage, privately held biotechnology company discovering and developing innovative protein and antibody therapeutics in the fields of oncology and immunology. Prior to Five Prime, Ms. Gregory was Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Ms. Gregory has been actively involved in a variety of public and private financings, including a private equity agreement designed to provide financing of up to $550 million for Lexicon and Lexicon's $220 million initial public offering. While at FivePrime and Lexicon, she led transactions for several strategic partnerships including those with GlaxoSmithKline, Human Genome Sciences, Genentech, Inc., Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. In addition, she led the negotiations for Lexicon's acquisition of the chemistry company that provided the foundation for Lexicon's novel drug programs. Prior to joining Lexicon, Ms. Gregory was an investment banker where she served as the head of investment banking for Punk, Ziegel & Company, a specialty technology and healthcare investment banking firm and was an investment banker with Dillon, Read & Co., Inc. She currently serves as a Director on the board of Clinipace on behalf of and as Special Advisor to Morgan Stanley Expansion Capital and on the board of The Global TB Alliance for Drug Development, primarily funded by the Gates Foundation.

Ms. Gregory received her B.A. from George Washington University's Elliott School of International Affairs where she was elected to Phi Beta Kappa and her M.B.A. from the Wharton School of the University of Pennsylvania.

 
David Low
David N. Low Jr.
 

David N. Low Jr.

David N. Low Jr.

Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical technology sectors. Mr. Low currently serves as a Senior Advisor at Lazard. From 2002 - 2013 Mr. Low was a member of Lazard's Life Sciences Group as a Managing Director. Mr. Low has advised on major M&A transactions in the life sciences, biotechnology and medical technology sectors, and has worked with private and public companies to raise capital, including emerging growth companies. Prior to joining Lazard, Mr. Low was a Managing Director at JP Morgan and a Senior Vice President at Lehman Brothers.

Mr. Low holds an A.B. from Harvard College, where he graduated cum laude, an M.A. from the Johns Hopkins University School of Advanced International Studies and an M.B.A. from Yale University.

Michael J. Otto, Ph.D.
Dr. Michael J. Otto
 

Michael J. Otto, Ph.D.

Michael J. Otto, Ph.D.

Dr. Otto served as Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. He led the research team responsible for the discovery of sofosbuvir for the treatment of HCV infections. In previous capacities he has served as Associate Director of Anti-Infectives Clinical Research at Rhône-Poulenc Rorer, Vice President for Research and Development at Avid Therapeutics, Inc., Research Manager at DuPont Pharmaceuticals and Dupont Merck Pharmaceuticals and as Group Leader in the Virology Dept. at Sterling Drug in Rensselaer, NY. Prior to joining Sterling drug, Dr. Otto was Research Assistant Professor at Yale University School of Medicine, Dept. of Pharmacology. Dr. Otto served as the US editor for Antiviral Chemistry & Chemotherapy from 1989 until 2012.

Dr. Otto holds a B.S. degree from Loyola University of Chicago and a Ph.D. degree in medical microbiology from The Medical College of Wisconsin. He is the author or coauthor of over 100 research papers and book chapters and named inventor on several patents and patent applications.

 

SCIENTIFIC ADVISORY BOARD

 
 
Vincent A. Fischetti, Ph.D.
Dr. Vincent A. Fischetti

Vincent A. Fischetti, Ph.D.

Professor and Chairman, Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University

Vincent A. Fischetti, Ph.D. Dr. Fischetti has been with The Rockefeller University since 1970 in various positions of increasing responsibility and prestige. He is a member of several advisory boards, including the New York Hall of Science and the New York Academy of Sciences. He is on the scientific advisory board and is a trustee of the Trudeau Institute. He has published more than 165 journal articles and more than 70 book chapters, and has been issued 40 U.S. patents. He serves as advisory editor for Trends in Microbiology and the Journal of Experimental Medicine, and was editor-in-chief of Infection and Immunity for ten years and a section editor for the Journal of Immunology.

Among his awards, Dr. Fischetti is the recipient of two National Institutes of Health MERIT awards. He is a member of the American Society for Microbiology and the Kunkel Society, and is the chair of the microbiology section of the New York Academy of Sciences.

He earned his B.S. in bacteriology from Wagner College in 1962 and his M.S. in microbiology from Long Island University in 1967. In 1970 he graduated with honors with a Ph.D. in microbiology from New York University School of Medicine.

Peter Palese, Ph.D.
Dr. Peter Palese

Peter Palese, Ph.D.

Chairman, Department of Microbiology,
Mount Sinai School of Medicine

Peter Palese, Ph.D. Dr. Palese has published more than 270 scientific articles on the replication of RNA-containing viruses, with a special emphasis on negative-strand RNA influenza viruses. He established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors, which are now FDA-approved antivirals. Dr. Palese also pioneered the field of reverse genetics for negative-strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. This technique is crucial for the study of the structure/function relationships of viral genes, for investigation of viral pathogenicity, and for development and manufacture of novel vaccines. In addition, an improvement of the technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent but extinct 1918 pandemic influenza virus. His recent work in collaboration with Dr. Adolfo Garcia-Sastre has revealed that most negative-strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host.

For his seminal studies on influenza viruses, Dr. Palese was elected to the National Academy of Sciences in 2000. He serves on the editorial board for the Proceedings of the National Academy of Sciences and as an editor for the Journal of Virology. He has been president of the Harvey Society and of the American Society for Virology. He received the Robert Koch Prize in 2006 and the Charles C. Shepard Science Award in 2008.

Dr. Palese received his Ph.D. in chemistry from the University of Vienna in 1969 and a Mag. Pharm. degree from the University of Vienna in 1970.

Adolfo Garcia-Sastre, Ph.D.
Dr. Adolfo Garcia-Sastre

Adolfo Garcia-Sastre, Ph.D.

Professor, Department of Microbiology,
Mount Sinai School of Medicine;
Co-director, Global Health & Emerging Pathogens Institute

Adolfo Garcia-Sastre, Ph.D. For 20 years, Dr. Garcia-Sastre's research interest has focused on the molecular biology of influenza viruses and several other negative-strand RNA viruses. During his post-doctoral training, he developed the first novel strategies for expression of foreign antigens by a negative-strand RNA virus, influenza virus. He has made major contributions to the influenza virus field, including the development of reverse genetics techniques allowing the generation of recombinant influenza viruses from plasmid DNA; the generation and evaluation of negative-strand RNA virus vectors as potential vaccine candidates against different infectious diseases, including malaria and AIDS, and the identification of the biological role of the nonstructural protein NS1 of influenza virus during infection: the inhibition of the type I interferon (IFN) system.

His research has resulted in more than 200 scientific publications and reviews.

Dr. Garcia-Sastre is a member of the editorial board of PLOS Pathogens, Journal of Virology, Virology, Journal of General Virology and Virus Research. He is a co-leader of the basic research component on viral therapeutics and pathogenesis at the North East Biodefense Center. He is also the director of the Center for Research on Influenza Pathogenesis, one of the six NIAID-funded Centers of Excellence for Influenza Research and Surveillance. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 was awarded with the distinction of 'paper of the year 2005' by Lancet.

Dr. Garcia-Sastre earned his B.S. in biological sciences and his M.S. in biochemistry from the University of Salamanca, Spain, in 1986. He obtained his Ph.D. in biochemistry from the University of Salamanca in 1990.

Christoph Renner, M.D.
Dr. Christoph Renner

Christoph Renner, M.D.

Director, Department of Internal Medicine and Oncology,
University Hospital, Zurich

Christoph Renner, M.D. Dr. Renner, a professor of experimental and clinical oncology at the University of Zurich, Switzerland, oversees research in the areas of tumor antigen discovery, antibody engineering, tumor targeting, and phage display. He formerly served as acting director of the hematology department and a group leader of the oncology department. He is a key investigator with the Ludwig Institute for Cancer Research, where he has defined several immunological targets for cancer therapy. As an expert in molecular immunology, Dr. Renner has published over 75 articles and reviews in scientific journals. He has also contributed chapters to a dozen cancer-related textbooks and letters. He holds four patents in antibody research and two patents related to RP1 regulation in T-cells and G250 fusion proteins.

Dr. Renner completed his undergraduate studies in chemistry at the University of Cologne in Germany, while working towards his M.D., which he received from the University of Cologne Medical School in 1993.

Charles Bailey, Ph.D.
Dr. Charles Bailey

Charles Bailey, Ph.D.

Distinguished Professor of Biology and Executive Director, George Mason University Biomedical Research Laboratory

Charles Bailey, Ph.D. Dr. Bailey has overseen a five-year building project that began in 2005 when George Mason University was awarded a $27.7 million grant from the NIAID. Prior to joining GMU, Dr. Bailey served as commander of the U.S. Army Medical Research Institute of Infectious Diseases, where he led medical and scientific research programs dedicated to the development of new forms of medical protection against biological weapons and infectious diseases. The results of his hands-on experiments with a wide variety of infectious agents have been published in more than 100 scientific articles in reference books and journals. He has presented at national and international conferences and to U.S. government officials, and has served as a senior analyst with the Defense Intelligence Agency.

Dr. Bailey retired from the U.S. Army as a Colonel. He holds B.S., M.S., and Ph.D. degrees in biology and entomology from Oklahoma State University.

Leon G. Smith, M.D., M.A.C.P.
Dr. Leon G. Smith

Leon G. Smith, M.D., M.A.C.P.

Distinguished Professor of Biology and Executive Director, George Mason University Biomedical Research Laboratory

Leon G. Smith, M.D., M.A.C.P. Dr. Smith served as Chief of Infectious Diseases at Saint Michael's Medical Center for 40 years before becoming Chairman of the hospital's Department of Medicine. He also serves as Chair of the Residency Program in Internal Medicine at Seton Hall University School of Graduate Medical Education and has taught medicine and preventive medicine at New Jersey Medical School. Dr. Smith developed the first viral diagnostic laboratory in New Jersey, as well as H.I.V. and Hepatitis C Clinics at Saint Michael's Medical Center.

Dr. Smith co-founded and participates in the Inter-City Infectious Disease Rounds Group, which meets weekly at New York City/New Jersey area hospitals. A past President of the National Foundation for Infectious Disease, Dr. Smith has published extensively on infectious diseases and has served on many committees of the Infectious Disease Society of America, which presented him with its Mentor Award for training more infectious disease fellows than anyone. He recently founded and funded the Infectious Disease Hall of Fame at Saint Michael's Medical Center.

He has received many awards, including the Clara Barton Award, the Best Doctors Award, and he has served as a consultant to the Vatican. Dr. Smith co-chairs the Medical Society of New Jersey's Bio-Terrorism Task Force and is a Master of the American College of Physicians.

Dr. Leon Smith is an alumnus of Georgetown Medical School, Yale Medical School, and the National Institutes of Health.

Daniel Capon
Dr. Daniel J. Capon

Daniel J. Capon, Ph.D.

Daniel Capon Dr. Capon is the co-inventor of several of biotech's leading products and technologies, including Fc fusion proteins (Genentech), recombinant Factor VIII for hemophilia (Genentech), XenoMouseTM for fully human antibodies (Abgenix), the PhenoSenseTM HIV drug resistance test (Monogram Biosciences), and Chimeric Antigen Receptors for T cell immunotherapy (Cell Genesys). He holds 43 U.S. Patents, which have been licensed for a number of biotech blockbuster drugs, including EnbrelTM, KogenateTM, VectibixTM and XgevaTM, representing over $12 billion in annual sales.

Dr. Capon has served in several scientific and business roles. In 1995, he co-founded Monogram to commercialize PhenosenseTM for the guidance of anti-retroviral therapy in AIDS patients. He was Chairman and CEO until 1999 and Chairman Emeritus until 2009, when Monogram was purchased by LabCorp. In 1991, he co-founded Xenotech (Abgenix) to commercialize XenoMouseTM, serving as co-Chairman and CEO until 1995. From 1990 to 1995, he also served as the VP Research and Chief Technical Officer at Cell Genesys, guiding its efforts towards the first FDA-approved clinical trials of Chimeric Antigen Receptors. Previously, he was a Genentech Staff Scientist, a member of Genentech's Product Development Committee, and led the project team responsible for the first FDA-approved clinical trials of Fc fusion proteins. In 1985, Dr. Capon's team published the first complete sequence of the AIDS virus (HIV) genome and transcriptome, its master blueprint, and in 1983, the first complete coding sequences of the H-ras and K-ras cancer genes in bladder, lung and colon cancer.

He received his B.S. in Biology (1976) and Ph.D. in Biochemistry (1981) from M.I.T.